Dr. Koehler brings over 20 years of oncology drug development leadership experience to Remix's Board of Directors WATERTOWN, Mass., June 18, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical ...
"The preclinical data for REM-422 provide strong therapeutic rationale for our ongoing Phase I study in AML and High-Risk MDS," said Peter Smith, Ph.D., President and Chief Executive Officer of Remix ...
WATERTOWN, Mass., June 18, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback